Editors note: The drugs are listed in alphabetical order.
- Adalimumab-Adbm injection: Boehringer Ingelheim Pharmaceuticals discontinued two presentations of Cyltezo, its biosimilar to Humira. The discontinuations of 4ct and 6ct starter packs for the drug were planned discontinuations and the 2ct packs are still available. The injectable medication is used for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and other conditions.
- Ezetimibe; Simvastin tablet: Merck has discontinued its cholesterol-lowering combination therapy. These products were expected to be unavailable starting in January.
- Gadobenate Dimeglumine Injection: Bracco Diagnostics reported a shortage of several presentations of this contrast agent. The company did not provide a reason for the shortage and resupply dates for the affected products remain uncertain.
- Lisdexamphetamine Dimesylate capsule: Shire Pharmaceuticals reported a continued shortage of several presentations of this ADHD medication due to a shortage of active ingredients. While some strengths remain available, the overall shortage is expected to persist indefinitely.
- Methotrexate Sodium injection: Hospira discontinued its 25 mg/1mL presentation of this chemotherapy agent. No resupply is expected, and the product will no longer be available after January.
- Ramelteon tablet: Eisai Co. discontinued multiple strengths of this insomnia medication. These products are expected to be unavailable starting in January.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
